Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.

The news likely didn't come as a big surprise to investors.Eli Lilly (LLY 1.53%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite the recent approval, Eli Lilly's stock isn't skyrocketing.Normally, when a healthcare stock receives positive news surrounding a much-anticipated treatment, ther ...